The new indications of the antidepressant drug Brintellix of Lingbei pharmaceutical have been supported by CHMP. This drug will soon become the first antidepressant approved in the EU to improve the cognitive function of patients with depression. The new indications are based on the results of the connecting test. The results show that when compared with placebo, vortioxetine and Lilly's antidepressant competitive product duloxetine can better improve various cognitive indexes of patients.
People with severe depression usually report a series of cognitive symptoms, including obvious difficulties in thinking, attention, and memory of new information, which can damage patients' self-confidence and lead to social disharmony. Although cognitive problems have been well recognized in other mental diseases such as schizophrenia, there are few studies on their impact on depression.
لنگبی ریسرچ اینڈ ڈویلپمنٹ کے ڈائریکٹر پیڈرسن نے کہا کہ ہمیں خوشی ہے کہ vortioxetine کو CHMP سے مثبت تبصرے ملے، خاص طور پر زیادہ تر مریضوں کے علاج کے نتائج کو متاثر کرنے میں علمی خرابی کی کیفیت۔ ہم نے علمی عوارض سے نمٹنے میں جو حوصلہ افزا اعداد و شمار دیکھے ہیں وہ ہمیں اس بات پر یقین کرنے کی طرف لے جاتے ہیں کہ vortioxetine بہت سے مریضوں کو ان کے ڈپریشن کے علاج میں مدد کرنے کی صلاحیت رکھتی ہے۔
Votexetine has been listed in the United States for only more than a year, and it is gradually lifted in the whole EU. Last September, it was listed in Denmark, Lingbei's hometown. It is reported that this drug is the fastest-growing new antidepressant in the United States in the past three years. This drug is jointly listed by Lingbei and Takeda in the United States.
یہ لنگبی کے لیے اچھی خبر ہے کیونکہ اسے اپنے پرانے اینٹی ڈپریسنٹ Idprem کے پیٹنٹ کے ختم ہونے سے ہونے والے اثرات کو پورا کرنے کے لیے نئی ادویات کی ضرورت ہے۔ Yidepulum کئی بلین ڈالرز کی سالانہ فروخت کے ساتھ ایک بلاک بسٹر دوا تھی، جو عام ادویات کے مقابلے سے متاثر ہوئی ہے۔
Votexetine sold 188 million kroner (27 million) in six EU markets last year, compared with 83 million kroner in the fourth quarter alone, so it still has some ways to catch up with Idem. Although Idprem no longer has a market franchise, it still sold 4.6 billion kroner. The Danish company also has long-acting schizophrenic drug aripiprazole and an alcohol addiction treatment drug nalmefene, which can help vortioxetine increase the company's revenue again.